This study provides a novel design strategy for bispecific antibodies targeting refractory tunnel lesions in hidradenitis suppurativa, suggesting that the spatial interactions between cells and multi-pathway synergistic mechanisms should be a key focus in the construction of autoimmune disease models.
Literature Overview
This article, titled "Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody," published in Signal Transduction and Targeted Therapy, systematically explores the unique synergistic pathogenic mechanisms of the IL-17 and IL-36 pathways in hidradenitis suppurativa (HS) and validates the superior efficacy of the bispecific antibody HB0043 in preclinical and early clinical trials.Background Knowledge
Hidradenitis suppurativa is a chronic inflammatory skin disease, with its core challenge lying in the difficulty of reversing deep tunnel structures using traditional single-target biologics. Current monotherapies targeting TNF-α, IL-17A, or IL-36 can improve superficial nodules but fail to effectively eliminate the complex inflammatory circuit composed of Th17 cells, fibroblasts, and keratinocytes. Research indicates that IL-36γ and IL-17A are highly co-localized spatially, forming a self-amplifying pathogenic hub, which is the key mechanistic bottleneck for the failure of existing monotherapy. This study leverages multi-omics technologies to dissect this spatial interaction network and develops a bispecific antibody capable of simultaneously blocking both pathways, aiming to break the anatomical barriers of refractory lesions.
Research Methods and Core Experiments
The authors integrated single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (ST-seq), and plasma proteomics to perform high-resolution analysis of skin lesions from hidradenitis suppurativa patients. The study first identified a specific subpopulation of migratory spinous keratinocytes located within tunnels, finding them to highly express IL-36γ and downstream genes of the IL-17 signaling pathway. In vitro co-culture experiments confirmed that synergistic stimulation by IL-17A and IL-36γ significantly promotes keratinocyte proliferation and inflammatory cytokine secretion, while activating neutrophils and inflammatory fibroblasts. Based on this mechanism, the team developed the bispecific antibody HB0043 targeting IL-36R and IL-17A, utilizing IL-36R as an anchor to enrich the neutralizing effect of IL-17A locally at the lesion site. In a proof-of-concept clinical trial (NCT06895499), safety and efficacy were evaluated in 15 patients with Hurley stage III disease, with anatomical changes in tunnels monitored dynamically via high-frequency ultrasound.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery offers a new paradigm for drug development: designing bispecific antibodies targeting spatial interaction hubs within complex inflammatory networks, which holds promise for solving fibrosis and anatomical destruction problems that traditional therapies cannot reverse. In terms of clinical monitoring, this study emphasizes the importance of combining high-frequency ultrasound with dynamic assessment of plasma biomarkers to more comprehensively reflect disease activity. Furthermore, this strategy sets new requirements for disease modeling; future animal or in vitro models must be capable of simulating the spatial synergistic effects of multiple cell types to accurately predict the efficacy of multi-target therapies.
Conclusion
By integrating multi-omics technologies with bispecific antibody development, this study successfully revealed the synergistic pathogenic mechanism driven by the IL-17 and IL-36 pathways in hidradenitis suppurativa and provided the first clinical evidence capable of achieving anatomical repair of deep tunnels. From laboratory mechanism elucidation to clinical proof-of-concept, this work not only establishes bispecific antibodies as a new cornerstone for treating refractory inflammatory diseases but also brings hope for transforming the care system for related diseases from mere symptom control to structural cure. Future research should focus on expanding sample sizes to verify its universality across different populations and exploring the potential application of this strategy in other autoimmune diseases with complex inflammatory microenvironments.
